The discussion is about the Oncotype DX genetic test, which allows for the assessment of the risk of disease recurrence and determines whether chemotherapy will benefit a specific patient. For many women, the test results allow them to avoid heavy and unnecessary treatment, public media reports. During the pilot project, the cost of the test was covered by the government. During this period, 208 breast cancer patients underwent the test. The biological material obtained during the biopsy in the operation was sent by the company "Genekor Latvija" to a specialized laboratory in the USA. According to the head of "Genekor Latvija," Anita Greivule, the results were indicative: for 76% of the examined women, chemotherapy would not have provided additional benefits, allowing them to avoid it. The economic effect was also significant. According to estimates by KPMG, due to more accurate treatment selection, the healthcare system benefited by more than one million euros. However, the pilot project ended in the spring, and government funding ceased. One of the first to face this problem was patient Linda. When her doctor ordered the test, she had to pay for it out of her own savings. After that, the woman sent appeals to the Minister of Health and other responsible officials. Other patients who need this test are forced to seek financial assistance from charitable foundations. Health Minister Hosam Abu Meri stated that he finds the results of the pilot project convincing and supports the inclusion of the test in the list of state-funded medical services. According to the minister, this approach aligns with the principles of personalized medicine: instead of prescribing therapy "just in case," doctors have the opportunity to choose treatment that will truly be effective for a specific patient right away. The minister reported that he intends to raise the issue of funding for the test this fall during the redistribution of the state budget. If the necessary funds can be found, the program may be operational by the end of the year. Otherwise, the expenses are planned to be included in the basic budget of the healthcare system starting next year. For now, women who urgently need to make treatment decisions are forced to seek funds for the test themselves, from which, in many cases, not only the choice of therapy depends but also the possibility of avoiding severe side effects of chemotherapy.